IL1B and Venous thrombosis: Moreover, the Canakinumab Anti-inflammatory Thrombosis Outcome Study has demonstrated the beneficial effect of anti-inflammatory therapy targeting IL-1β on a recurrent cardiovascular event (22, 80).